

ASX RELEASE

28 May 2018

Dr. Warwick Tong appointed as Chairman

Innate Immunotherapeutics Limited (ASX: IIL) is pleased to announce that Dr. Warwick Tong has been appointed Chairman of the Board of Directors. Warwick brings 20 years of international clinical, commercial, and drug development leadership experience in both the pharmaceutical and biotechnology industries.

Warwick was appointed as a Director of Innate on the 4th of May 2018, following the Company's successful acquisition of Amplia Therapeutics Pty Ltd (Amplia) and currently serves as a member of the Company's Audit and Risk Committee. Previously he was the Cancer Research UK (CRUK) appointed director to the Board of Amplia. CRUK is the licensor of the Focal Adhesion Kinase (FAK) program acquired from Amplia and through that transaction they have become a strategically important shareholder of Innate Immunotherapeutics.

Managing Director Simon Wilkinson, stated "we are delighted that Warwick has accepted the position of Chairman. This is an important time from Innate as we implement the Company's turn-around strategy and complete the integration of the Amplia assets into our strategic roadmap. We expect our corporate governance structure to continue to evolve over the coming months but Warwick's leadership through the clinical translation of the FAK program will be of tremendous benefit to Innate."

Biography : Dr. Warwick Tong MB, ChB, MPP, GAICD

From 2011 until April of this year Dr. Tong was Chief Executive Officer of Cancer Therapeutics Cooperative Research Centre (CTx) and he continues as director of the CTx commercialisation company (CTxONE). Prior to CTx he was Senior Vice President Development for Surface Logix Inc, Boston USA and held senior positions at GlaxoSmithKline (GSK), including country, regional and global roles as in medical affairs, business development and served as Vice President Commercial Strategy for GSK's infectious diseases division. He also worked in primary care medicine for 14 years, founding two medical clinics in New Zealand. Dr. Tong is a qualified physician and graduated as a Senior Scholar in Medicine from the University of Auckland. He holds a postgraduate qualification in Public Policy from Victoria University (NZ) and is a graduate of the Australian Institute of Company Directors.

About Innate Immunotherapeutics Limited:

Innate Immunotherapeutics Limited (ASX: IIL) is an Australian pharmaceutical company that is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Innate has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Corporate Contact:

Mr Simon Wilkinson
Managing Director and CEO
Email: simon@innateimmuno.com

- End